Giorgio Patelli
Overview
Explore the profile of Giorgio Patelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galli E, Patelli G, Villa F, Gri N, Mazzarelli C, Mangoni I, et al.
Cancer Treat Rev
. 2025 Mar;
135:102908.
PMID: 40058162
Background: Relapse after radical treatment remains a major concern in hepatocellular carcinoma (HCC), affecting 50-75 % of early-stage cases within 5 years. Early recurrence prediction is a clinical unmet need....
2.
Mauri G, Patelli G, Crisafulli G, Siena S, Bardelli A
Cell
. 2025 Feb;
188(3):589-593.
PMID: 39919707
The incidence of early-onset colorectal cancer (EO-CRC) is surging, and by 2030, one-third of all CRCs will occur before the commonly recommended screening age of 50 years. The time required...
3.
Mauri G, Patelli G, Sartore-Bianchi A, Abrignani S, Bodega B, Marsoni S, et al.
Cell Rep Med
. 2024 Sep;
5(9):101737.
PMID: 39260369
Since the nineties, the incidence of sporadic early-onset (EO) cancers has been rising worldwide. The underlying reasons are still unknown. However, identifying them is vital for advancing both prevention and...
4.
Roazzi L, Patelli G, Bencardino K, Amatu A, Bonazzina E, Tosi F, et al.
Clin Colorectal Cancer
. 2024 Mar;
23(4):295-308.
PMID: 38519391
Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular...
5.
Mauri G, Patelli G, Roazzi L, Valtorta E, Amatu A, Marrapese G, et al.
J Clin Pathol
. 2024 Feb;
78(3):195-201.
PMID: 38350716
Background: Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, gene copy number loss ( loss) confers a selective dependency on the...
6.
Patelli G, Mauri G, Tosi F, Amatu A, Bencardino K, Bonazzina E, et al.
Clin Cancer Res
. 2023 Jul;
29(22):4530-4539.
PMID: 37436743
In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the identification of druggable alterations is pivotal to achieve the best therapeutic opportunity for each patient. Because the number...
7.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, et al.
Front Oncol
. 2023 Apr;
13:1147497.
PMID: 37056342
[This corrects the article DOI: 10.3389/fonc.2022.1030232.].
8.
Mauri G, Gori V, Patelli G, Roazzi L, Rizzetto F, De Carlis L, et al.
World J Surg Oncol
. 2023 Mar;
21(1):118.
PMID: 36998040
Background: Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited...
9.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, et al.
Front Oncol
. 2022 Nov;
12:1030232.
PMID: 36419886
Background: We aim to identify the prevalence and the role of the mutation in predicting resistance to anti-EGFR agents in metastatic colorectal cancer (mCRC) patients. Methods: We retrospectively reviewed tumor-based...
10.
Vaghi C, Mauri G, Agostara A, Patelli G, Pizzutilo E, Nakamura Y, et al.
Cancer Treat Rev
. 2022 Nov;
112:102488.
PMID: 36410093
ERBB2 amplification is a driver oncogenic alteration in many cancers and it has recently been incorporated among therapeutically actionable biomarkers also in metastatic colorectal cancer (mCRC). In contrast, the role...